{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T09:10:46Z","timestamp":1753521046520},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["mdconsult.com","theclinics.com","labmed.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.cll.2014.06.003","type":"journal-article","created":{"date-parts":[[2014,7,30]],"date-time":"2014-07-30T21:46:01Z","timestamp":1406756761000},"page":"443-452","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacology and Safety of New Oral Anticoagulants"],"prefix":"10.1016","volume":"34","author":[{"given":"Jerrold H.","family":"Levy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cll.2014.06.003_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.mcna.2007.09.002","article-title":"Status of the epidemiology of atrial fibrillation","volume":"92","author":"Kannel","year":"2008","journal-title":"Med Clin North Am"},{"issue":"2","key":"10.1016\/j.cll.2014.06.003_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/ajh.21917","article-title":"Prevalence of clinical venous thromboembolism in the USA: current trends and future projections","volume":"86","author":"Deitelzweig","year":"2011","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.cll.2014.06.003_bib3","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1097\/ALN.0b013e318289bcba","article-title":"Managing new oral anticoagulants in the perioperative and intensive care unit setting","volume":"118","author":"Levy","year":"2013","journal-title":"Anesthesiology"},{"key":"10.1016\/j.cll.2014.06.003_bib4","series-title":"Dabigatran prescribing information","year":"2013"},{"key":"10.1016\/j.cll.2014.06.003_bib5","series-title":"Dabigatran product monograph","year":"2012"},{"key":"10.1016\/j.cll.2014.06.003_bib6","series-title":"Dabigatran summary of product characteristics","year":"2012"},{"key":"10.1016\/j.cll.2014.06.003_bib7","series-title":"Dabigatran prescribing information","year":"2013"},{"key":"10.1016\/j.cll.2014.06.003_bib8","unstructured":"Boehringer Ingelheim pharmaceuticals I. PRAZAXA\u00ae (dabigatran etexilate) approved in Japan for stroke prevention in atrial fibrillation 2011. Available at: https:\/\/www.boehringer-ingelheim.com\/news\/news_releases\/press_releases\/2011\/21_january_2011_dabigatranetexilate.html. Accessed July 4, 2014."},{"key":"10.1016\/j.cll.2014.06.003_bib9","series-title":"Apixaban summary of product characteristics","year":"2011"},{"key":"10.1016\/j.cll.2014.06.003_bib10","series-title":"Apixaban prescribing information","year":"2012"},{"key":"10.1016\/j.cll.2014.06.003_bib11","series-title":"Apixaban product monograph","year":"2012"},{"key":"10.1016\/j.cll.2014.06.003_bib12","series-title":"Rivaroxaban prescribing information","year":"2013"},{"key":"10.1016\/j.cll.2014.06.003_bib13","series-title":"Rivaroxaban product monograph","year":"2013"},{"key":"10.1016\/j.cll.2014.06.003_bib14","series-title":"Rivaroxaban summary of product characteristics","year":"2013"},{"key":"10.1016\/j.cll.2014.06.003_bib15","series-title":"Edoxaban package insert","year":"2011"},{"key":"10.1016\/j.cll.2014.06.003_bib16","unstructured":"Available at: http:\/\/www.clinicaltrials.gov. Accessed September 30, 2013."},{"issue":"5","key":"10.1016\/j.cll.2014.06.003_bib17","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1161\/CIRCOUTCOMES.112.966572","article-title":"Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation","volume":"5","author":"Baker","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"20","key":"10.1016\/j.cll.2014.06.003_bib18","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1161\/CIRCULATIONAHA.112.115410","article-title":"Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature","volume":"126","author":"Dentali","year":"2012","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.cll.2014.06.003_bib19","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.cll.2014.06.003_bib20","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"9855","key":"10.1016\/j.cll.2014.06.003_bib21","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(12)60986-6","article-title":"Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial","volume":"380","author":"Lopes","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.cll.2014.06.003_bib22","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.cll.2014.06.003_bib23","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip replacement","volume":"363","author":"Lassen","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.cll.2014.06.003_bib24","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.cll.2014.06.003_bib25","unstructured":"US Food and Drug Administration approves Kcentra for the urgent reversal of anticoagulation in adults with major bleeding. 2013 Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/Pressannouncements\/ucm350026.htm. Accessed November 5, 2013."},{"key":"10.1016\/j.cll.2014.06.003_bib26","unstructured":"US Food and Drug Administration. Coumadin official FDA information, side effects and uses. 2011. Available at: http:\/\/www.drugs.com\/pro\/coumadin.html. Accessed September 30, 2013."},{"issue":"12","key":"10.1016\/j.cll.2014.06.003_bib27","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2165\/00003088-200342120-00003","article-title":"Pharmacodynamic and pharmacokinetic properties of enoxaparin: implications for clinical practice","volume":"42","author":"Fareed","year":"2003","journal-title":"Clin Pharm"},{"key":"10.1016\/j.cll.2014.06.003_bib28","unstructured":"sanofi-aventis. Enoxaparin\u2014Highlights of prescribing information. 2008. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020164s083lbl.pdf. Accessed November 5, 2013."},{"issue":"13","key":"10.1016\/j.cll.2014.06.003_bib29","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1161\/CIRCULATIONAHA.109.853119","article-title":"New anticoagulants","volume":"121","author":"Eikelboom","year":"2010","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.cll.2014.06.003_bib30","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/MBC.0b013e3283494b3c","article-title":"Protamine reversal of low molecular weight heparin: clinically effective?","volume":"22","author":"van Veen","year":"2011","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"10.1016\/j.cll.2014.06.003_bib31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/j.gastro.2013.02.041","article-title":"New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis","volume":"145","author":"Holster","year":"2013","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cll.2014.06.003_bib32","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/1076029613486539","article-title":"The efficacy and safety of oral anticoagulants in warfarin-suitable patients with nonvalvular atrial fibrillation: systematic review and meta-analysis","volume":"19","author":"Mitchell","year":"2013","journal-title":"Clin Appl Thromb Hemost"},{"issue":"9","key":"10.1016\/j.cll.2014.06.003_bib33","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc1112874","article-title":"Bleeding risk with dabigatran in the frail elderly","volume":"366","author":"Harper","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.cll.2014.06.003_bib34","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7326\/0003-4819-157-10-201211200-00532","article-title":"Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review","volume":"157","author":"Adam","year":"2012","journal-title":"Ann Intern Med"},{"issue":"14","key":"10.1016\/j.cll.2014.06.003_bib35","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJMp1302834","article-title":"Dabigatran and postmarketing reports of bleeding","volume":"368","author":"Southworth","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2014.06.003_bib36","unstructured":"US Food and Drug Administration. Pradaxa (dabigatran etexilate mesylate): drug safety communication\u2014safety review of post-market reports of serious bleeding events. 2012. Available at: http:\/\/www.fda.gov\/safety\/medwatch\/safetyinformation\/safetyalertsforhumanmedicalproducts\/ucm282820.htm. Accessed August 30, 2013."},{"issue":"14","key":"10.1016\/j.cll.2014.06.003_bib37","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"B\u00fcller","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.cll.2014.06.003_bib38","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMoa0810773","article-title":"Apixaban or enoxaparin for thromboprophylaxis after knee replacement","volume":"361","author":"Lassen","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.cll.2014.06.003_bib39","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"9717","key":"10.1016\/j.cll.2014.06.003_bib40","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial","volume":"375","author":"Lassen","year":"2010","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.cll.2014.06.003_bib41","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.cll.2014.06.003_bib42","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/clc.22081","article-title":"Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin","volume":"36","author":"Dogliotti","year":"2013","journal-title":"Clin Cardiol"},{"issue":"1","key":"10.1016\/j.cll.2014.06.003_bib43","first-page":"40","article-title":"Comparative effectiveness of novel oral anticoagulants for atrial fibrillation: evidence from pair-wise and warfarin-controlled network meta-analyses","volume":"5","author":"Biondi-Zoccai","year":"2013","journal-title":"HSR Proc Intensive Care Cardiovasc Anesth"},{"issue":"12","key":"10.1016\/j.cll.2014.06.003_bib44","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1161\/STROKEAHA.112.673558","article-title":"Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Ntaios","year":"2012","journal-title":"Stroke"},{"issue":"21","key":"10.1016\/j.cll.2014.06.003_bib45","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1161\/CIRCULATIONAHA.113.002332","article-title":"Management and outcomes of major bleeding during treatment with dabigatran or warfarin","volume":"128","author":"Majeed","year":"2013","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.cll.2014.06.003_bib46","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-156-10-201205150-00421","article-title":"Oral direct factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis","volume":"156","author":"Neumann","year":"2012","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.cll.2014.06.003_bib47","doi-asserted-by":"crossref","first-page":"275","DOI":"10.7326\/0003-4819-159-4-201308200-00008","article-title":"Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review","volume":"159","author":"Adam","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cll.2014.06.003_bib48","unstructured":"Sobieraj DM, Coleman CI, Tongbram V, et\u00a0al, editors. Venous thromboembolism prophylaxis in orthopedic surgery. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012. Mar. Report No.: 12-EHC020-EF."},{"issue":"Suppl 2","key":"10.1016\/j.cll.2014.06.003_bib49","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.cll.2014.06.003_bib50","first-page":"68","article-title":"Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management","volume":"68","author":"Levi","year":"2010","journal-title":"Neth J Med"},{"issue":"5","key":"10.1016\/j.cll.2014.06.003_bib51","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1160\/TH11-05-0358","article-title":"Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA)","volume":"106","author":"Pengo","year":"2011","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.cll.2014.06.003_bib52","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1160\/TH12-03-0209","article-title":"Management consensus guidance for the use of rivaroxaban\u2014an oral, direct factor Xa inhibitor","volume":"108","author":"Turpie","year":"2012","journal-title":"Thromb Haemost"},{"issue":"27","key":"10.1016\/j.cll.2014.06.003_bib53","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/eurheartj\/eht134","article-title":"EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary","volume":"34","author":"Heidbuchel","year":"2013","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.cll.2014.06.003_bib54","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/cc12592","article-title":"Clinical review: clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications","volume":"17","author":"Lazo-Langner","year":"2013","journal-title":"Crit Care"},{"issue":"24","key":"10.1016\/j.cll.2014.06.003_bib55","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1182\/blood-2012-05-423228","article-title":"Perioperative management of patients on chronic antithrombotic therapy","volume":"120","author":"Ortel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.cll.2014.06.003_bib56","unstructured":"US Food and Drug Administration. Safety announcement\u2014Updated recommendations to decrease risk of spinal column bleeding and paralysis in patients on low molecular weight heparins. 2013. Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM373735.pdf. Accessed November 5, 2013."},{"issue":"5","key":"10.1016\/j.cll.2014.06.003_bib57","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1160\/TH11-10-0718","article-title":"Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice","volume":"107","author":"Huisman","year":"2012","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.cll.2014.06.003_bib58","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1055\/s-0038-1649639","article-title":"Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins","volume":"70","author":"Young","year":"1993","journal-title":"Thromb Haemost"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027227121400047X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027227121400047X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T19:47:04Z","timestamp":1598125624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027227121400047X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S027227121400047X"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2014.06.003","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacology and Safety of New Oral Anticoagulants","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2014.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}